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1. Introduction
Liver biopsy (LB) is the most common procedure performed in clinical hepatology. His‐
tological  assessment  of  the  liver,  and  thus,  LB  is  traditionally  the  “reference  standard”
in the diagnosis and management of parenchymal liver diseases. Definitive diagnosis of‐
ten depends on LB,  and much of  understanding of  the characteristic  features and natu‐
ral  history  of  liver  diseases  is  based  on  information  obtained  by  serial  liver  biopsies.
During  the  last  60  years  as  the  result  of  a  better  understanding  of  liver  disorders,  ap‐
pearance  of  newer  entities  and advent  of  novel  hepatic  imaging techniques,  the  indica‐
tions  for  LB  have  evolved.  Whereas  in  the  past  LB  was  often  performed  as  the  initial
investigation in the workup of liver disease of unknown aetiology, today the most com‐
mon indication for  LB includes  staging of  chronic  hepatitis.  A variety  of  methods exist
for  getting  a  liver  tissue  specimen.  These  take  account  of  a  percutaneous  method,  a
transvenous (transjugular or transfemoral) approach, and intra-abdominal biopsy (laparo‐
scopic or laparotomic). All LB techniques require specific training so as to ensure appro‐
priate-sized  specimen  retrieval  and  the  lowest  rate  of  complications.  However,  because
LB  is  an  invasive  procedure  that  carries  a  definite,  albeit  small,  risk  of  complications,
controversy  persists  with  regard  to  its  precise  indications  in  various  clinical  situations,
its  clear  contraindications,  the  optimal  technique  for  its  performance  (and whether  cer‐
tain modifications improve its  safety),  and training requirements  for  clinicians.  The aim
of  this  chapter  will  be  summarize  the  existing clinical  practice  of  LB with an emphasis
on  the  technique,  indications,  contraindications,  quality  of  LB  specimens  and  risk  of
complications.
© 2012 Randazzo et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Indications
Historically, LB was applied almost exclusively as a diagnostic tool [1]. Nevertheless, as the
result of natural history data and the introduction of many new therapies for patients with
liver disease, histological assessment of the liver has now got on an important role in clinical
management. Therefore, LB currently has three major indications: for diagnosis, for assess‐
ment of prognosis and/or to assist in the management of patient with known liver disease.
Diagnosis
•Identification and staging of parenchymalandcholestatic liver diseases
-alcoholic liver disease
-non-alcoholic steatohepatitis
-autoimmune hepatitis
-primary biliary cirrhosis
-primary sclerosing cholangitis
-metabolic and mitochondrial storage liver diseases such as Wilson’s disease, hemochromatosis, Gaucher’s disease
•Evaluation of persistent abnormal liver biochemical tests after negative or inconclusive serologic workup
•Evaluation of the type and extent of drug-induced liver injury
•Evaluation of fever of unknown origin or immunocompromised patients with hepatomegaly or elevated liver
enzymes levels
•Diagnosis of multisystem infiltrative disorders
- Identification and determination of the nature of focal/ diffuse intrahepatic abnormalities on imaging studies
Prognosis - Staging of known liver disease
•Evaluation of pre-transplant living-related donor
•Evaluation of post-transplant patient with abnormal liver tests (rejection vs. infectious aetiology)
Management – Developing treatment plans based on histologic analysis
•Pre-treatment evaluation and staging of chronic hepatitis
•Evaluation of effectiveness of therapies for liver diseases (eg, autoimmune hepatitis)
Table 1. Indications for liver biopsy
LB is performed to evaluate diffuse parenchymal or focal liver disease (see table 1). LB is
mainly helpful in patients with diagnostic uncertainty(eg, in patients with atypical features).
Available data show that liver histology will, in a proportion of patients, point to a specific
diagnosis [2] and lead to a change in patient management [3,4]. LB has long been considered
as an important diagnostic adjunct in the evaluation of otherwise unexplained abnormalities
of liver biochemical tests. For example, LB may exclude serious liver disease or detect un‐
suspected non-alcoholic fatty liver disease (NAFLD) or intrahepatic sclerosing cholangitis
after an otherwise negative biochemical, serologic and radiologic evaluation [3]. Needle LB
for diagnosis remains important in cases of coexisting disorders such as steatosis and HCV
[5] or an “overlap” syndrome of primary biliary cirrhosis (PBC) with autoimmune hepatitis
(AIH) [6].
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Other indications for LB include documentation of alcoholic liver disease and assessment of
its severity; evaluation of otherwise unexplained fever, particularly in patients with Ac‐
quired Immune Deficiency Syndrome (AIDS); detection of underlying granulomatous liver
disease. LB also provides important diagnostic information regarding drug-induced liver in‐
jury. Liver histology is appropriately considered in conjunction with clinical and laboratory
data in case of hereditary disorders, eg hemochromatosis (quantitation of the level of iron),
Wilson’s disease (quantitation of the level of copper), and alpha-1 antitrypsin deficiency.
Liver histology may also be useful in detection of infiltrative processes such as amyloidosis
[7]. Moreover, liver histology is often helpful in the setting of acute liver failure (ALF) [8].
An additional main use of LB is in assessing disease severity, particularly fibrosis, which, as
a precursor to cirrhosis, may predict the emergence of complications of portal hypertension
and also liver-related morbidity and mortality.
Owing to the wide use and superior resolution of cross-sectional imaging such as ultraso‐
nography (US), computed tomography, and magnetic resonance imaging, focal lesions are
being detected more often. Fortunately, the same technologic advances allow us to confi‐
dently establish a diagnosis without biopsy in most cases. Nevertheless, sometimes a biopsy
of a suspected neoplasm will help change management. In this case, careful consideration of
biopsy technique is important, as neoplasms have a higher bleeding risk and the potential to
seed other sites along the biopsy tract or in the abdominal cavity [9]. At present, most biop‐
sies currently performed for parenchymal disease are not to make a specific diagnosis but to
assess liver damage, particularly in situations where (prognostic) information about fibrosis
may guide consequent treatment. For example, histological analysis of the liver in patients
with chronic HCV-induced liver disease gives information about the grading (inflammatory
activity) and the staging (degree of fibrosis) that predict the course of disease; the treatment
is often advocated for those with at least moderate to severe staging, but may be withheld
when fibrosis is minimal or absent [10]. Liver histology is also generally used in disease
monitoring of patients with AIH [11]. Monitoring the plasma cell score on LB may help pre‐
dict relapse when a physician is considering reducing or discontinuing immunosuppressive
therapy [12]. For further information on the role of histological analysis in the management
of individual liver diseases, is possible to see guidelines for HCV [10], HBV [13], hemochro‐
matosis [14], cholestatic liver diseases [15], AIH [11], and Wilson’s disease [16].
Assessment of liver histology after orthotopic liver transplantation (OLT) is highly valuable
to assess for allograft rejection and the presence and intensity of disease recurrence. Contro‐
versy persists regarding the precise indications for LB. Among these controversies are the
following:
• The precise cut-off of serum aminotransferase levels that should prompt a LB: any persis‐
tent elevation, 1.5 times the upper normal limit, or 2 standard deviations above the mean
[17,18]. Even the definition of the upper limit of normal is controversial [19-21].
• The need for LB in patients presumed to have NAFLD. Whereas imaging studies are sen‐
sitive for detecting steatosis, they are relatively not sensitive and nonspecific for detecting
inflammation and fibrosis. Only on liver histology can distinguish fatty liver from steato‐
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hepatitis, which can lead to fibrosis and cirrhosis. LB is often considered if serum alanine
aminotransferase (ALT) levels remain elevated after a modification of lifestyle and risk
factors [22].
• The need for LB in all patients with PBC and primary sclerosing cholangitis (PSC). In
most cases the diagnosis can be established on the basis of a cholestatic pattern of liver
chemistries and either anti-mitochondrial antibodies in PBC [6] or endoscopic retrograde
cholangiopancreatography (ERCP) in PSC [23]; scoring systems based on quickly estab‐
lished clinical variables could be used to assess prognosis and response to therapy.
• The need for protocol liver biopsies in all liver transplant recipients. A high rate of histo‐
logic abnormalities in the absence of liver biochemical test abnormalities has been descri‐
bed as late as 10 years after transplantation [24].
Overall, in patients without a definitive pre-biopsy diagnosis, LB has been shown to change
the clinical diagnosis in 8% to 10% and to change the management in 12% of patients [25].
However, changes in management are often of minor importance [3].
3. Biopsy technique
Performance of  LB requires  an adequate sized and dedicated space suitable  for  focused
physician effort  as  well  as  safe  patient  recovery.  There  are  different  approaches for  ob‐
taining  liver  tissue:  percutaneous,  transjugular,  laparoscopic,  and  intraoperative,  each
having  advantages  and  disadvantages.  The  biopsy  technique  is  chosen  on  the  basis  of
the indication, risks,  and benefits in the individual patient.  The most common approach
for collecting a liver sample is percutaneous LB, either blinded or under US guidance. It
is  quick  and  safe  procedures  commonly  performed  by  gastroenterologists  or  hepatolo‐
gists in out-patient settings.
A variety of needles are available for percutaneous LB; they are broadly classified into suc‐
tion needles (Menghini, Klatskin, Jamshidi), cutting needles (Vim-Silverman, Tru-cut), and
spring-loaded cutting needles that have a triggering mechanism. The choice of a specific
type of needle depends in part on local preference. Cutting needles usually produce a larger
sample and are less likely to yield inadequate specimens than are suction needles, but they
probably result in more complications [26], probably because the needle remains in the liver
longer. Cutting needles can be useful in patients with cirrhosis. Suction needles are quicker
(in the liver for a briefer time), easier to use, and less expensive, but tend to produce more
fragmented samples. Disposable biopsy needles and biopsy guns are often used. A typical
biopsy gun uses a modified 18-, 16-, or 14-gauge Tru-cut needle that is fired by a fast and
powerful spring mechanism.
If the patient is not relaxed, a mild sedative should be administered just before the biopsy
[27]. The current data on the use of prophylactic antibiotics is inconclusive. Prophylactic an‐
tibiotics have been recommended for patients at increased risk of endocarditis or with bili‐
ary sepsis [28]. However, recent results suggest that prophylactic administration of
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antibiotics following apercutaneous liver biopsy does not have a significant impact on the
post-procedure results or incidence of infection [29]. During the procedure, patients placed
in the supine position with the right hand resting behind the head [30]. For the blind ap‐
proach (also referred to as the percussion-palpation approach), caudal percussion is helpful
in selecting the site for the biopsy over the hemithorax between the anterior and mid-axil‐
lary lines, until an intercostal space is reached where dullness is maximal at the end of expi‐
ration. The intercostal space below this point (usually in the 7th-8th intercostal space) is used.
A local anesthetic, typically lidocaine (without adrenaline), is administered with a 25-gauge
needle first subcutaneously and into the intercostal muscle and finally down to the dia‐
phragm and the capsule of the liver to reduce pain. The biopsy is performed while the pa‐
tient holds a breath in full expiration [31]. With a suction needle, aspiration is applied, and
the needle is rapidly introduced perpendicularly to the skin into the liver and withdrawn
quickly (within 1 second). This is the critical step in performing the biopsy to minimize the
risk of lacerating the liver and inducing bleeding. If insufficient tissue is obtained on the first
pass [32], a second pass is performed at a different angle. After the biopsy, the patients is
usually kept on the right lateral decubitus position for up to 2 hours to reduce the risk of
bleeding and the pulse and blood pressure are monitored. Post-procedure monitoring has
evolved over time. Most complications manifest within the first few hours [26], and under
certain circumstances more and more patients are being discharged just 1 or 2 hours after
imaging-guided biopsy. Rightly, the recommended observation time after biopsy is between
2 to 4 hours. To direct the needle away from other organs and large vascular structures,
physicians often use US guidance. The US has been used either throughout the entire proce‐
dure (real-time) or immediately before (site marking) through a technique in which the pa‐
tient subsequently has LB performed at the marked site. US guidance is the most
controversial issue associated with LB [33-35]. Potential LB sites marked by percussion were
changed in between 3 and 15% of patients after US was performed [36,37]. In an uncontrol‐
led Italian study, routine identification of the puncture site by US led to a diagnostic tissue
sample in 99% of patients [35]. In diffuse liver disease, US marking or guidance has been
associated with lower rates of pain, hypotension, and bleeding [31]. In a survey of 2084 liver
biopsies in France, US guidance is used in 56% of cases (in 34% to determine the puncture
site and in 22% to guide the biopsy) and is thought to reduce the frequency of severe com‐
plications [38]. Cost-effectiveness analyses have suggested that routine US guidance in clini‐
cal practice increases the cost of LB but may be cost-effective, with an incremental cost of
$2731 to avoid one major complication [39,40]. In addition, a large, randomized, prospective
trial found that US use lowered the rate of post-biopsy hospitalization (most common rea‐
son for hospital admission was pain). Indeed there is a long track record of safety for per‐
forming percutaneous LB without imaging guidance. Thus, the role of US to guide
percutaneous LB remains controversial. Use of ultrasound is not mandatory. A transjugular
biopsy route offers a reasonable alternative to standard biopsy in high-risk patients (eg pres‐
ence of massive ascites, severe coagulopathy, morbid obesity with a difficult to identify
flank site or fulminant hepatic failure) [41]. With transjugular LB, the liver tissue is obtained
from within the vascular system, which minimizes the risk of bleeding [42,43]. The proce‐
dure is performed by interventional radiologists or hepatologists under X-ray videofluoro‐
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scopy. Electrocardiographic monitoring is required to detect arrhythmias induced by
passage of the catheter through the heart [41,44]. The patient is positioned supinely, with the
head rotated opposite to that of the right internal jugular vein to be punctured, under local
anesthesia using the Seldinger technique; then, a catheter is introduced into the hepatic vein
under fluoroscopic control, and a needle biopsy of the liver performed through the catheter.
Samples are retrieved from a Menghini or Tru-cut needle passed through the catheter into
the liver. The transjugular approach permits concomitantly measurement of hepatic venous
pressure gradient or opacification and imaging of the hepatic veins and inferior vena cava
[45] helping in the diagnosis and management of select group of patients, particularly those
with cirrhosis. In the past, a drawback of transjugular biopsy was the small and fragmented
samples obtained. Better needles and more experience have led to improved quality of
specimens. However, a transjugular LB is available only at a limited number of tertiary care
facilities. Mortality is low (0.09%) [41], but perforation of the liver capsule can be fatal [46].
With laparoscopic approach, specific lesions can be identified and targeted precisely; thus it
is especially useful in the diagnosis of peritoneal disease, the evaluation of ascites of un‐
known origin and abdominal mass, the staging of abdominal cancer. Laparoscopic LB is a
safe procedure that can be performed under local anesthesia with conscious sedation, al‐
though it requires expertise that is not readily available. Absolute contraindications include
severe cardiopulmonary failure, intestinal obstruction, bacterial peritonitis; relative contra‐
indications are severe coagulopathy, morbid obesity, and a large ventral hernia [33]. For
most parenchymal liver diseases, the extra time and cost required for laparoscopy are not
justified by the increased yield. Liver biopsies (needle or wedge) can also be obtained dur‐
ing abdominal surgery whenever liver disease is suspected. In many instances, an abnormal
appearance of the liver during surgery for an unrelated procedure (most often cholecystec‐
tomy) is the first indication of an underlying liver disease. It is generally performed either
with typical needle devices or by wedge resection by those with special expertise. While in‐
traoperatively obtained liver biopsies have the added advantage of obtaining adequate tis‐
sue sampling under direct vision from grossly visible/suspicious lesions, they are
suboptimal for assessment of liver fibrosis and inflammation, due to preponderance of Glis‐
sen’s capsule, wider portal tracts in the subcapsular area, and frequent but inconsequential
surgically induced hepatitis. Other advantages are the ability to evaluate for potential extra‐
hepatic spread of malignancy and to look for a cause of unexplained ascites (peritoneal bi‐
opsy). The major disadvantages are cost and the added risk of anesthesia. Therefore, needle
biopsy should be the technique of choice at laparotomy.
4. Contraindications
Although LB is often essential in the management of patients with liver disease, physicians
and patients may find it to be a difficult undertaking because of the associated risks.
The consensus guidelines of contraindications for percutaneous LB are listed in Table 2.
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Absolute
•Uncooperative patient
•History of unexplained bleeding
•Tendency to bleed
-Prothrombin time "/> 3-4 sec over control
-Platelet counts < 50.000/mm3
-Prolonged bleeding time (≥10 min)
•Unavailability of blood transfusion support
•Recent use of aspirin or other nonsteroidal anti-inflammatory drugs (within last 7-10 days)
Relative
•Ascites
•Morbid obesity
•Infection in the right pleural cavity or below the right hemidiphragm
•Suspected hemangioma or other vascular tumor
•Hydatid disease (Echinococcal cysts)
Table 2. Contraindications to percutaneous LB
Percutaneous LB with or without image guidance is appropriate only in cooperative pa‐
tients. As for any procedure, the patient that undergoes a LB should be able to understand
and cooperate with the physician’s instructions. An academic concern is that if the patient
accidentally moves when the biopsy needle is in the liver, then a tear or laceration may oc‐
cur (which would in turn greatly increase the risk of bleeding). Thus uncooperative patients
who require LB should undergo the procedure under general anesthesia or via the transve‐
nous route.
Coagulopathy is generally considered a contraindication to percutaneous LB, but the precise
parameters that preclude LB are unsettled [47]. Generally, LB should be withdrawn when
the prothrombin time (PT) is more than 3-4 seconds above the control value (International
Normalized Ratio, INR>1.5) or when the platelet count is less than 60.000/mm3 [48]. Never‐
theless, it is important to emphasize that the relationship of abnormal indices of peripheral
coagulation to the occurrence of bleeding after LB in patients with acute as well as chronic
liver disease is uncertain, as limited data are available [47,49]. In patients with mild to mod‐
erate prolongation of PT, administration of fresh frozen plasma or appropriate clotting fac‐
tor concentrates may allow safe performance of a LB, as in hemophiliacs [50]. A low platelet
count is probably less likely to result in bleeding in a cirrhotic patient with hypersplenism
than in a leukemic patient with a comparable platelet count but platelet dysfunction. Proba‐
bly, platelet dysfunction due to aspirin use is a major risk factor as well. Whether patients
with renal insufficiency are at increased risk of bleeding complications after LB is also un‐
certain [28]. In summary, the decision to perform LB in the setting of abnormal hemostasis
parameters should continue to be reached as the result of local practice because there is no
specific INR and/or platelet count cut-off at or above which potentially adverse bleeding can
be reliably predicted.
Liver Biopsy: An Overview
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A LB is precluded by tense ascites, because the liver will bounce away from the needle,
thereby preventing adequate sampling of tissue, and the ascites will provide insufficient
tamponade in case of bleeding. In patients with tense ascites requiring a LB, a transvenous
approach is commonly recommended. Acceptable options include total paracentesis per‐
formed immediately prior to percutaneous biopsy or transvenous or laparoscopic biopsy.
Relative contraindication is morbid obesity; in this case, transjugular biopsy is a logical al‐
ternative.
A standard LB is probably contraindicated by extrahepatic biliary obstruction, bacterial
cholangitis, and the risk of bleeding after LB appears to be increased in patients with a
known hematologic malignancy involving the liver [28].
Although LB in patients with mass lesions is usually safe, biopsy of known vascular lesions
(ie hepatic hemangioma) should generally be avoided [51]. Patients who require LB and
who have a large vascular lesion identified on imaging should undergo the procedure using
real-time image guidance. Biopsy of potentially malignant lesions should be undertaken
with care because it is believed that tumour vessels are more likely to bleed [51] and it can
be also associated with a risk of tumour spread [52,53].
Biopsy of infectious lesions is generally safe. In the past, the presence of an echinococcal cyst
was considered a contraindication to LB, because of the possibility of disseminating cysts
throughout the abdomen and the risk of anaphylaxis. However, with recent advances in
treatment, echinococcal cysts can be aspirated safely under ultrasound guidance [54].
5. Complications
When performing a LB, should be aware of multiple potential complications that may occur
after biopsy.At the time that informed consent is obtained, it is reasonable to outline these
complications clearly, warn the patient of the potential pain, and mention in a general state‐
ment that other complications, albeit rare, can occur.
Although the percutaneous biopsy is invasive, associated complications are rare, occurring
in up to 6%, and 0.04% to 0.11% can be life threatening [33].
The different complication rates were attributed to variation in technique and to differences
in the needles used, as well as differences in the severity of the liver disease and selection
criteria in different centers.
The most common complication after percutaneous LB is pain [55]. Approximately 25% of
patients have pain in the right upper quadrant or right shoulder; the pain is usually dull,
mild and brief. Right upper-quadrant pain does not seems to be related to approach (i.e.
subcostal vs. intercostal) [56]. The mechanism of pain following percutaneous biopsy is most
likely a result of bleeding or possibly bile extravasation from the liver puncture wound,
with subsequent capsular swelling, although the exact mechanism remains uncertain [57].
When present, pain can generally be managed with small amounts of narcotics. A decision
Liver Biopsy - Indications, Procedures, Results10
about when to investigate with imaging and/or to hospitalize the patient for observation
due to pain should be made on a case-by-case basis.
MAJOR
•Dearth
•Haemorrhage (intraperitoneal, intrahepatic, haemothorax)
•Perforation of the gallbladder or of the bowel
•Pneumothorax, haemothorax
•Biopsy of the right kidney or the pancreas
•Intrahepatic arteriovenous fistula
•Bile peritonitis
MINOR
•Pain (biopsy site, right upper quadrant and right shoulder pain)
•Transient hypotension (vasovagal response)
•Pneumoperitoneum
•Hemobilia
•Infection (bacterial sepsis, local abscess)
•Intrahepatic and subcapsular hematoma
Table 3. Complications of percutaneous liver biopsy
Transient hypotension, due to vasovagal reaction, can occur, particularly in patients who are
frightened or emotional.
Major complications were defined as life threatening or those that required hospitalization,
prolonged hospitalization or those that resulted in persistent or significant disability. Most
serious complications occur within 24 hours of the procedure, and 60% happen within 2
hours; between 1% and 3% of patients require hospitalization [33].
The most common serious complication is bleeding because of transection of a vascular
structure [26]; bleeding may occur in the absence of pain. Mild bleeding, defined as that suf‐
ficient to cause pain or reduced blood pressure or tachycardia, but not requiring interven‐
tion, occurs in about 1/500 biopsies [58]. Severe bleeding is defined clinically by a change in
vital signs with imaging evidence of intraperitoneal bleeding. Such bleeding has been esti‐
mated to occur in between 1 in 2.500 to 1 in 10.000 biopsies after a percutaneous approach
for diffuse liver disease [59]. Although very rare, clinically significant intraperitonealhemor‐
rhage is the most serious bleeding complication of percutaneous LB; it usually becomes ap‐
parent within the first 2-3 hours after the procedure [26]. Free intraperitoneal blood may
result from laceration of the liver capsule caused by deep inspiration during the biopsy or
may be related to a penetrating injury of a branch of the hepatic artery or portal vein. The
likelihood of hemorrhage increased with older age, presence of cirrhosis or liver cancer, and
number of passes (≥ 3) with the needle during biopsy. The relationship between LB compli‐
cations and the number of needle passes is well documented [51]. The frequency of compli‐
cations increased with the number of passes performed at a rate of 26.4%, with one pass vs.
Liver Biopsy: An Overview
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68% with two or more passes (P< 0.001) [38]. An additional factor in determining the risk of
hemorrhage may be the type of needle used; cutting needles are more likely to result in
hemorrhage than suction needles [26]. Severe bleeding requires hospitalization and is most
often managed expectantly with placement of intravenous catheters, volume resuscitation
by the administration of intravenous fluids and blood transfusion as necessary. If hemody‐
namic instability persists for a few hours despite the use of aggressive resuscitative meas‐
ures, angiography with selective embolization of the bleeding artery or surgery (to ligate the
right hepatic artery or resect a section) is required.
Subclinical bleeding leading to intrahepatic or subcapsular hematomas may be noted after
LB even in asymptomatic patients. It is occurs in up to 23% of patients [60] and can be de‐
tectable by US. Large hematomas may cause pain associated with tachycardia, hypotension,
and a delayed decrease in the hematocrit [33]. Conservative treatment of hematomas is gen‐
erally sufficient.
After tranvenous biopsy bleeding is extremely rare because of the Glisson capsule is not
breached except as a procedural complication from within the liver [61].
The least common of the hemorrhagic complications is hemobilia, which usually presents
with the classic triad of gastrointestinal bleeding, biliary pain, and jaundice [26] approxi‐
mately 5 days after the biopsy [62].
Transient bacteremia has been reported in 5.8 to 13.5 percent of patients after LB [63], and
although such bacteremia is generally inconsequential, septicaemia and shock can rarely oc‐
cur in patients with biliary obstruction and cholangitis.
Biliary peritonitis caused by puncture of the gallbladder is rare (0.00001% frequency) but
can be fatal [64].
Pneumothorax, hemothorax, subcutaneous emphysema, perforation of any of several organs
(lung, colon, and kidney), subphrenic abscess are other complications reported with LB.
Pneumothorax may be self-limited but may require more aggressive intervention depending
on the severity of symptoms. Visceral perforation is usually managed expectantly. In most
situations, observation is all that is required, although surgical intervention may be needed
in the case of gallbladder puncture and persistent bile leak, or in the case of secondary peri‐
tonitis.
Differences in complication rates, either minor or major, have been reported between the
blind and US-guided LB. The use of US guidance can prevent inadvertent puncture of other
organs or large intrahepatic vessels. US may also reduce the incidence of major complica‐
tions such as haemorrhage, bile peritonitis, pneumothorax, etc.
With respect to the impact of the experience of the operator to the rate of complications, the
evidences are controversial. A survey performed in Switzerland showed that the complica‐
tion rate of percutaneous LB was mainly related to the experience and training of the opera‐
tor, in particular a lower complication rate was reported for physicians who performed
more than 50 biopsies a year [65]. Another study showed that the rate of complications in
percutaneous LB was 3.2% if the operator had performed <20 biopsies, and only 1.1% if the
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operator had performed more than 100 biopsies [64] In contrast, Chevallier et al. showed
that the operator’s experience did not influence either the final histological diagnosis or the
degree of pain suffered by patients [66].
In adult series, the rate of major complications associated with transjugular LB is low (0.5%;
liver puncture-related, 0.2%; non-liver puncturerelated,0.3%), considering that it is currently
performed in patients with coagulopathy [41]. Minor complications were significantly more
frequent with Menghini needle, possibly related with the difficulty in controlling the depth
of puncture increasing the risk of capsular penetration [46].
MINOR
Pyrexia
Neck hematoma, bleeding
Neck pain
Carotide puncture
Transient Horner’s syndrome
Transient dysphonia
Arm numbness/palsy
Supraventricular arrhythmia
Hypotension
Abdominal pain
Subclinical capsular perforation
Small hepatic hematoma
Hepatic-portal vein fistula
Hepatic artery aneurysm
Biliary fistula
Haemobilia
MAJOR
Large hepatic hematoma
Intraperitoneal haemorrhage
Inferior vena cava or renal vein perforation
Ventricular arrythmia
Pneumothorax
Respiratory arrest
Table 4. Complications of transjugular liver biopsy
Factors associated with liver and non-liver puncture related complication rates included
number of passes (liver puncture-related), young age, and number of transjugular biopsies.
The complications after laparoscopic LB include perforation of a viscus, bleeding, hemobilia,
laceration of the spleen, leakage of ascitic fluid, hematoma in the abdominal wall, vasovagal
reaction, prolonged abdominal pain, and seizures [67].
The most quoted mortality rate after percutaneous LB is less than or equal to 1/10.000 biop‐
sies. Mortality is typically related to bleeding. Mortality is highest among patients who un‐
dergo biopsies of malignant lesions. Cirrhosis is another risk factor for fatal bleeding after
LB. Mortality after transvenous biopsy was 0.09% [41] in adult series, but may reflect the se‐
lection of higher risk patients for this intervention. Indeed, mortality is significantly higher
in children; smaller livers and horizontal hepatic veins may increase the technical difficulty
and risk of capsular perforation, which might be minimized by combined fluoroscopic and
US guidance [68].
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6. Pathological considerations
Even though LB gives significant diagnostic and prognostic information and helps define
treatment plans, it must be recognized that sampling variability and intra observer variabili‐
ty may restrain the diagnostic value of LB. The quality of LB is usually determined by
length, width, fragmentation and complete portal tracts (CPTs) [33].
Sample size can affect the diagnostic accuracy of LB specimens [33]. s almost always means
that size of the needle biopsy specimen should be of large enough size to accurately assess
the degree of liver injury. Considering that a biopsy sample taken from an adult corre‐
sponds to a fraction of just 1/50,000th of the whole liver, a biopsy specimen would seem to
be inadequate in the case of diffuse diseases, such as a chronic viral hepatitis, in which the
liver changes may be unevenly distributed.
Several studies demonstrated that cirrhosis can be missed on a single blind percutaneous LB
in 10%-30% of cases [69-71]. In a detailed study, Colloredo et al. [72] carefully evaluated the
impact of sample size on correct stadiation of liver fibrosis in patients with chronic hepatitis
C. By reducing progressively the dimensions of the same LB, they reported that the smaller
the sample analyzed, the milder the diagnosis made by the pathologist with respect to the
stage of fibrosis. The reduction in length (<2 cm) led to a significant decrease in number of
complete portal tracts and underestimation of grading and staging. The study by Colloredo
et al also introduced the concept of a ‘‘minimum number of CPTs.’’ Since the number of por‐
tal tracts is proportional to biopsy size [73], there was evidence that with fewer than 11 to 15
CPTs grade and stage are significantly underestimated [72]. The lower number of complete
portal tracts may explain the lower diagnostic accuracy obtained with smaller samples
[73,74]. Guido and Rugge have suggested that a biopsy sample ≥20 mm containing at least
11 CPTs should be considered reliable for adequate staging [75]. Other authors have recom‐
mended even bigger samples, up to 25 mm in length [76]. Scheuer suggested that ‘‘bigger is
better’’ [77]. Very recently, the American Association for the Study of Liver Diseases
(AASLD) has recommended a biopsy sample of at least 20–30 mm in length, and containing
at least 11 CPTs [48].
In summary, an adequate (although probably still imperfect) sample needs to be at least 2
cm long (1.4 mm width, 16G) and to contain no fewer than 11 CPTs. These criteria have been
adopted rapidly as optimal standards.
Of equal importance to adequate specimen size is the necessity that a pathologist experi‐
enced in liver disease interprets the biopsy, ideally in partnership with the clinician who
performed  the  biopsy  and/or  whom  is  caring  for  the  patient.  Rousselet  et  al.  reported
that the degree of experience of the pathologist (specialization, duration, and location of
practice) may have a significant impact on the diagnostic interpretation of LB, even high‐
er than that related to characteristics of the specimen (length, fibrosis class number, mis‐
cellaneous factors) [78].
Assessment of disease severity with liver histology is supported by a wide body of liter‐
ature [79]. Complex scoring systems, such as the Knodell scoring system [80] and its re‐
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vised form, the Ishak scoring system [81]  have been developed for grading and staging
of chronic viral hepatitis, and there is now a similar score for steatohepatitis [82]. Never‐
theless, these are not highly reproducible and are only appropriate for statistical analysis
of (large) cohorts of patients in clinical trials. In clinical practice, it was recommended to
use the simple systems with three to four categories such as METAVIR [83] rather than
complex (Ishak) scoring system [48].
7. Further research
Until a few years ago, LB was the only tool for the diagnosis of liver disease. However, the
indications for performing a LB have undergone changes in the last decade. Given the inva‐
sive nature of LB, several simple and non-invasive methods (radiologic, immunologic, bio‐
chemical, genetic markers) have been studied and proposed as surrogates of liver histology.
The main advantages of serum biomarkers vs. LB include being less invasive and the possi‐
bility to be easily repeated to monitor the status of liver disease. However, at this time, they
are primarily useful for detecting advanced fibrosis or for excluding minimal or no fibrosis.
They are not sufficiently accurate for assessing disease progression or the effect of therapy.
Due to inadequate diagnostic accuracy or to lack of sufficient validation, current guidelines
do not recommend serum biomarkers a substitute for LB that is still considered the refer‐
ence standard. Notably, non-invasive serum biomarkers, when combined, may reduce by
50%-80% the number of liver biopsies needed for correctly classifying hepatic fibrosis. Se‐
rum biomarkers for liver fibrosis are particularly useful for the initial assessment as well as
for long-term monitoring of particular subsets of patients (ie, chronic hepatitis C). In this
view, combination algorithms of the most validated non-invasive methods for liver fibrosis
and LB represent a rational approach to the diagnosis of liver fibrosis in chronic liver diseas‐
es. Novel imaging techniques, such as measuring the elasticity of the liver using transient
elastography (Fibroscan) [84], may assess fibrosis more directly. However, the use of such
techniques in routine clinical practice has not been well defined and require further investi‐
gation. LB cannot be avoided completely, but should be used in those cases in which non-
invasive methods show poor accuracy. Nevertheless, large scale, prospective, independent
studies are needed in other aetiologies of CLDs. Many questions about LB remain and they
require much more research. For instance, it is not clear which biopsy devices or techniques
are best. In addition, few if any studies have assessed the biopsy's long-term effects. Because
the liver is cut and bleeds during procedure, there will be some subsequent scarring.
8. Conclusions
LB continues to play a central role in the evaluation of patients with suspected liver disease,
but many aspects of the procedure remain controversial. For example, the precise degree of
serum ALT elevations that should prompt a LB is debated, as is the need for LB in all pa‐
tients with suspected NAFLD and chronic hepatitis C. The importance of LB in arriving at a
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diagnosis of diffuse parenchymal liver disease is being diminished by accurate blood testing
strategies for chronic viral hepatitis, autoimmune hepatitis, and primary biliary cirrhosis.
Further, imaging tests are superior to LB in the diagnosis of primary sclerosing cholangitis.
However, many cases remain in which diagnostic confusion exists even after suitable labo‐
ratory testing and imaging studies. Diagnosing infiltrative disease (eg, amyloidosis, sarcoi‐
dosis), separating benign fatty liver disease from steatohepatitis, and evaluating liver
parenchyma after liver transplantation are best accomplished by LB.
Percutaneous LB is contraindicated in patients with severe coagulopathy and ascites, but
the degree of coagulopathy that contraindicates a LB is controversial.  Also controversial
are the technical aspects of LB, particularly the choice of needle (cutting vs. suction) and
the  use  of  US  to  mark  or  guide  the  biopsy  site.  Bleeding  is  the  major  complication  of
LB,  with  a  risk  of  0.3%;  cutting  needles  are  more  likely  to  cause  hemorrhage  than  are
suction needles.  While needle biopsy is still  the mainstay in diagnosing hepatic fibrosis,
its days of dominance seem limited as technology improves. When physical examination
or standard laboratory tests reveal clear-cut signs of portal hypertension, LB will seldom
add useful information. Similarly, when imaging studies provide compelling evidence of
cirrhosis and portal hypertension, needle biopsy is not warranted. The combination algo‐
rithms warrant further evaluation in all chronic liver diseases, as they may help decrease
the number of liver biopsies required. Moreover, transient elastography is playing an ev‐
er-increasing role  in  the  assessment  of  hepatic  fibrosis  and will  significantly  reduce the
need for biopsy in patients with liver disease.
Clearly, as our knowledge of various liver disorders advances and new especially non-inva‐
sive diagnostic tests are developed, the role of LB in medical practice will continue to
evolve. Emergence of better imaging techniques, surrogate serological markers of liver fibro‐
sis are among the many new and exciting developments that hold promise for the future.
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